Saturday , May 30 2020
Home / le News / Swiss research leads to cancer break through

Swiss research leads to cancer break through

Summary:
Researchers at the Paul Scherrer Institute recently deciphered the structure of the CC chemokine receptor 7 (CCR7), a signaling protein. © Bogdan Hoda | Dreamstime.comCancer cells use CCR7 to guide themselves into the lymphatic system, spreading cancer throughout the body. The resulting secondary tumors, called metastases, are responsible for most cancer deaths. This new understanding of CCR7 is a break through that forms a foundation for developing drugs that could lead to treatments to reduce the spread of certain types of cancer, including colorectal cancer, the second most common malignant tumor worldwide. Based on this work, scientists at the Swiss pharmaceutical giant Roche found a number of compounds in their database that might block the CCR7 signaling protein and that

Topics:
Investec considers the following as important: , , ,

This could be interesting, too:

Investec writes Swiss have mixed feelings about working from home, according to survey

Investec writes Swiss employer must pay employee’s rent, rules court

Investec writes 40% of Swiss restaurants unsure of survival under current restrictions

Investec writes Coronavirus: Switzerland plans to lift all restrictions on Schengen movement

Researchers at the Paul Scherrer Institute recently deciphered the structure of the CC chemokine receptor 7 (CCR7), a signaling protein.

Swiss research makes cancer break through CCR7
© Bogdan Hoda | Dreamstime.com

Cancer cells use CCR7 to guide themselves into the lymphatic system, spreading cancer throughout the body. The resulting secondary tumors, called metastases, are responsible for most cancer deaths.

This new understanding of CCR7 is a break through that forms a foundation for developing drugs that could lead to treatments to reduce the spread of certain types of cancer, including colorectal cancer, the second most common malignant tumor worldwide.

Based on this work, scientists at the Swiss pharmaceutical giant Roche found a number of compounds in their database that might block the CCR7 signaling protein and that could be used to develop new drugs to reduce the spread of cancer.

The Paul Scherrer Institute is Switzerland’s largest research institute, with 2,100 staff and an annual budget of around CHF407 million, according to the Institute’s website.

More on this:
Discovery article published in Cell (in English)

For more stories like this on Switzerland follow us on Facebook and Twitter.

About Investec
Investec
Investec is a distinctive Specialist Bank and Asset Manager. We provide a diverse range of financial products and services to our niche client base.

Leave a Reply

Your email address will not be published. Required fields are marked *